

DAFTAR PUSTAKA

- Addis Ababa. (2019). Implementation manual for DTG rollout and ART optimization in Ethiopia. Ethiopia: Federal Democratic Republic of Ethiopia Ministry of Health.
- Anwar, Y., Nugroho, S., & Wulandari, S. (2018). Profi L Efek Samping Antiretrovirus Pada Pasien HIV/AIDS Di RSPI Prof. Dr. Sulianti Saroso Jakarta Jurnal Ilmu Kefarmasian Indonesia, 16(1), 49-55.
- Christensen, E. S., Jain, R., & Roxby, A. C. (2017, July). Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient. In Open forum infectious diseases (Vol. 4, No. 3). Oxford University Press.
- Clay, P. G., Nag, S., Graham, C. M., & Narayanan, S. (2015). Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. *Medicine*, 94(42).
- Dooley, K. E., Kaplan, R., Mwelase, N., Grinsztejn, B., Ticona, E., Lacerda, M., & Aboud, M. (2020). Dolutegravir-based antiretroviral therapy for patients coinfecting with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. *Clinical Infectious Diseases*, 70(4), 549-556.
- Fettiplace, A., Stainsby, C., Winston, A., Givens, N., Puccini, S., Vannappagari, V., & Curtis, L. (2017). Psychiatric symptoms in patients receiving dolutegravir. *Journal of acquired immune deficiency syndromes (1999)*, 74(4), 423.

Geng, E. H., Bwana, M. B., Muyindike, W., Glidden, D. V., Bangsberg, D. R., Neilands, T. B., ... & Martin, J. N. (2013). Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 63(2), e64-e71.

Holec, A. D., Mandal, S., Prathipati, P. K., & Destache, C. J. (2017). Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. *Current HIV research*, 15(6), 411-421.

Kementerian Kesehatan Republik Indonesia. (2015). Petunjuk Teknis Pengisian Formulir Pencatatan dan Pelaporan Program Pengendalian HIV AIDS dan IMS. Jakarta: Direktorat Kementerian Kesehatan RI (Diunduh pertama kali: 9 November 2022).

Kementerian Kesehatan Republik Indonesia. (2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK. 01.07/Menkes/90/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. Jakarta: Direktorat Kementerian Kesehatan RI (Diunduh pertama kali: 29 September 2022).

Kementerian Kesehatan Republik Indonesia. (2021). Laporan Perkembangan Kasus HIV/AIDS Tahun 2021. Jakarta: Direktorat Kementerian Kesehatan RI (Diunduh pertama kali: 28 Oktober 2022).

Kementerian Kesehatan Republik Indonesia. (2022). Peraturan Menteri Kesehatan No. 23 Tahun 2022 tentang Penganggulan Human Immunodeficiency Virus (HIV), Aquired Immunodeficiency Virus Syndrome (AIDS), dan Infeksi Menular Seksual (IMS). Jakarta: Direktorat Kementerian Kesehatan RI (Diunduh pertama kali: 28 Oktober 2022).

- Kementerian Kesehatan Republik Indonesia. (2017). Program Pengendalian HIV/AIDS dan PIMS Fasilitas Kesehatan Tingkat Pertama. Jakarta: Direktorat Kementerian Kesehatan RI (Diunduh pertama kali: 26 Maret 2023).
- Kim, S. H., Gerver, S. M., Fidler, S., & Ward, H. (2014). Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. *AIDS (London, England)*, 28(13), 1945.
- Lv, Z., Chu, Y., & Wang, Y. (2015). HIV protease inhibitors: a review of molecular selectivity and toxicity. *Hiv/aids (Auckland, NZ)*, 7, 95.
- Meintjes, G., Moorhouse, M. A., Carmona, S., Davies, N., Dlamini, S., Van Vuuren, C., & Venter, F. (2017). Adult antiretroviral therapy guidelines 2017. *Southern African journal of HIV medicine*, 18(1), 1-24.
- Mofenson, L. M., Pozniak, A. L., Wambui, J., Raizes, E., Ciaranello, A., Clayden, P., & Ford, N. P. (2019). Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. *Journal of the International AIDS Society*, 22(7), e25352.
- Mulyadi, M., & Fitrika, Y. (2012). Hubungan tuberkulosis dengan HIV/AIDS. *Idea Nursing Journal*, 2(2), 162-166.
- Odeny, T. A., Padian, N., Doherty, M. C., Baral, S., Beyrer, C., Ford, N., & Geng, E. H. (2015). Definitions of implementation science in HIV/AIDS. *The Lancet HIV*, 2(5), e178-e180.
- Ramjan, R., Calmy, A., Vitoria, M., Mills, E. J., Hill, A., Cooke, G., & Ford, N. (2014). Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. *Tropical Medicine & International Health*, 19(5), 501-513.

- Savira, M. (2017). Imunologi Human Immunodeficiency Virus (HIV) dalam Kehamilan. *Jurnal Ilmu Kedokteran (Journal of Medical Science)*, 8(1), 1-7.
- Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke Jr, T. R., & Hughes, S. H. (2021). Integrase strand transfer inhibitors are effective anti-HIV drugs. *Viruses*, 13(2), 205.
- Soerijadi, A., & Dewi, S. M. (2019). Gambaran jumlah CD4+ pasien HIV yang melakukan terapi cART di RSPI Prof. Sulianti Saroso periode Januari 2014–Desember 2016. *Tarumanagara Medical Journal*, 1(3), 474-480.
- Taha, H., Das, A., & Das, S. (2015). Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. *Infection and drug resistance*, 339-352.
- Usach, I., Melis, V., & Peris, J. E. (2013). Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. *Journal of the International AIDS Society*, 16(1), 18567.
- Wang, Z., Shang, H., & Jiang, Y. (2017). Chemokines and chemokine receptors: accomplices for human immunodeficiency virus infection and latency. *Frontiers in immunology*, 8, 1274.
- World Health Organization. (2016). *The use Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach: Switzerland.*
- World Health Organization. (2018). *Update Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Recommendations for a Public Health Approach: Switzerland.*

World Health Organization. (2021). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach: Switzerland.

Wu, P. H., Lin, Y. T., Hsieh, K. P., Chuang, H. Y., & Sheu, C. C. (2015). Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a nationwide population-based study. *Medicine*, 94(33).

Xiong, S., Borrego, P., Ding, X., Zhu, Y., Martins, A., Chong, H., & He, Y. (2017). A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. *Journal of virology*, 91(1), e01839-16.

Yuliyanasari, N. (2017). Global burden disease–human immunodeficiency virus–acquired immune deficiency syndrome (hiv-aids). *Qanun Medika-Medical*

